Trial Profile
A Multicenter Phase II Open Label Study to Evaluate Efficacy of Concomitant Use of Pembrolizumab and Entinostat in Adult Patients With Metastatic Uveal Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Entinostat (Primary) ; Pembrolizumab (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- Acronyms PEMDAC
- 17 Feb 2022 Status changed from active, no longer recruiting to completed.
- 25 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 22 Feb 2018 Planned End Date changed from 1 Jul 2023 to 1 Aug 2023.